Blog

DEEP RESEARCH · TOMOCUBE

Tomocube Deep Dive: Holotomography Moat and Overhang Risk

A review of second-generation holotomography, animal-testing alternatives, and industrial expansion potential

Published: 2025-08-18 · Deep-tech company analysis · Original Naver Blog post

You are responsible for your own investment decisions. This material is research and is not a buy or sell recommendation.

0. Bottom line first

Tomocube is framed as a deep-tech 3D cell-imaging company that commercialized second-generation holotomography. The long-term appeal is non-invasive 3D cell analysis, organoid/cell-therapy/drug-discovery demand, and non-bio expansion into semiconductors. The near-term risks are 32.2% post-listing float and profitability verification before the expected 2026 turnaround.

Technology

Second-generation HT

Non-invasive 3D imaging of live cells and organoids without staining.

Market

Animal-test alternatives

Organoid-based preclinical research could expand after FDA Modernization Act 2.0.

Risk

32.2% overhang

The post lists post-listing tradable shares at about 32.2% of total shares.

1. Company and business model

Official fact: Tomocube was founded in 2015 by KAIST physics professor Park Yong-keun and CEO Hong Ki-hyun. The business develops and sells holotomography-based 3D cell microscopes and AI analysis software, with HT-X1 and HT-2H as representative products.

  • The post mentions distribution in more than 30 countries and deliveries to over 200 research institutions in more than 50 countries.
  • TomoAnalysis is described as achieving more than 97% toxicity-detection accuracy.
  • Exports represented 63.5% of 2023 revenue, and revenue grew from KRW 600mn in 2019 to KRW 1.8bn in 2022.

2. Technical moat: observing live cells as they are

Official fact: HT is described as sending light through cells or organoids from multiple directions, measuring refractive-index changes, and reconstructing the data into 3D images like CT. The key difference is long-term observation of live cells without fluorescent staining or chemical treatment.

How holotomography worksNon-invasive 3D cell imaging
LightMultiple directions
Refractive indexInternal cell information
3D reconstructionCT-like method
AI analysisAccuracy and efficiency
The core is analyzing live cells and organoids without staining.

Interpretation: The claimed five-year-plus technology gap and ability to analyze sub-micron organelles in 3D support the standard-setting narrative. The investment case still depends on translating that into sales, repeat demand, and software monetization.

3. Shareholder structure and float

TimingTradable sharesShare of total
Listing day4,095,78632.17%
After 1 month2,599,89020.42%
After 3 months1,805,47814.18%
After 12 months930,040Only share count shown in the source table
After 36 months3,300,00025.92%

Interpretation: The source table, based on a Eugene Investment report, flags large post-listing and one-month supply. The founders' three-year lockup partly aligns long-term management incentives.

4. Competition and market opportunity

ItemTomocubeIVIM Technology
Imaging methodHolotomography, label-free non-invasive 3DIntravital microscopy, confocal and two-photon microscopy
Main targetEx-vivo cells, organoids, tissue-like modelsCells and tissues inside live animals
ApplicationsDrug discovery, cell therapy, organoids, semiconductor non-destructive inspectionDisease pathophysiology and drug efficacy/side-effect observation

FDA Modernization Act 2.0 is framed as allowing alternatives to animal testing in drug development. The post explains the backdrop as the inefficiency of animal testing, where 90-95% of candidates that pass animal studies fail in human trials, and sees organoid-based preclinical research as a demand driver for Tomocube.

5. Management, industrial expansion, and conclusion

  • Professor Park leads source technology and R&D, while CEO Hong leads commercialization and market strategy.
  • Park Systems CEO Park Sang-il's outside-director role is linked to possible expansion into semiconductor advanced packaging inspection and glass-substrate inspection.
  • My read: Tomocube is an interesting deep-tech candidate across technology, regulation, and applications, but near-term overhang, losses, and sales ramp speed need confirmation.

Sources

Naver original